CD19 and systemic lupus erythematosus: The fourth study (NCT05765006) is a Phase I, open-label, single-arm, multicenter trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-CD19 CAR T therapy (Relma-cel) in patients with moderate-to-severe active SLE.